<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399384</url>
  </required_header>
  <id_info>
    <org_study_id>2014-6352</org_study_id>
    <nct_id>NCT02399384</nct_id>
  </id_info>
  <brief_title>Pericardial Fat and Inflammation in HIV Patients and Controls</brief_title>
  <official_title>Myocardial Adipose Inflammation and Pericardial Adipose Volume as Markers for Coronary Artery Disease In HIV Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to correlate 1) cardiac MRI pericardial adipose volume, 2) the
      presence of pericardial monocytes and 3) circulating immune biomarkers in persons with and
      without CHD and HIV infection compared to seronegative controls with known CHD. The
      investigators aim to test the hypothesis that higher amounts of pericardial fat deposition
      and increased presence of monocytes within this adipose tissue are associated with underlying
      coronary artery disease in persons with HIV infection as measured by cardiac MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods and Procedures:

      Screening Assessments Patients who potentially meet inclusion criteria will be identified
      through the Infectious Disease Center and/or the cardiac catheterization laboratory who have
      had a coronary angiogram or cardiac CT angiogram, with or without evidence of CAD. Their
      records will be reviewed for inclusion and exclusion criteria and informed consent will be
      obtained prior to any research related procedures by a member of the research team for this
      project.

      A screening visit will be done to obtain informed consent. BUN and Creatinine will be done at
      screening to ensure the safety of the MRIprocedure.

      In HIV-infected subjects who have not had HIV-1 RNA or CD4+ lymphocyte tests obtained in the
      last 60 days, these will be done at screening.

      Screening visits will last approximately 30-60 minutes.

      Entry Visit - MRI The entry visits will occur within 14 days of the screening assessment. All
      female patients of child bearing potential will have a negative pregnancy test.

      If BUN/Creatinine results are greater than 14 days old, they will be repeated STAT prior to
      beginning MRI procedure.

      Whole blood will be drawn for biobanking (PBMCs, Plasma and Serum) as well as fasting lipids
      will be obtained.

      An IV will be started in the MRI laboratory. All participants will undergo an initial cardiac
      MRI with contrast for the evaluation of cardiac function, chamber size, resting perfusion,
      pericardial adipose volume/mass, myocardial edema and determination of infarction.

      The GE Signa Horizon 1.5T Magnet will be used to obtain all images. Sequences obtained will
      include Double IR, Triple IR, T2 Stars, SSFP and delayed gadolinium enhancement imaging.

      After the initial CMR on day 1, Feraheme 5 mg/kg IV will be administered. Feraheme (30 mg/mL)
      is available for intravenous injection in single use vials. Each vial contains 510 mg of
      elemental iron in 17 mL.

      Feraheme will be administered as an undiluted intravenous injection delivered at a rate of up
      to 1 mL/sec (30 mg/sec) through a filtered needle.

      Patients will be monitored for 1 hour after administration for signs of allergic reaction.

      The total amount of time for the Entry visit will be about 4 hours. Day 2 or 3 - repeat MRI A
      second, limited cardiac MRI will be obtained 48-72 hours after injection of Feraheme to
      determine the presence of monocyte/macrophages in adipose tissue.

      The GE Signa Horizon 1.5T Magnet will be used to obtain all images. Imaging with T2 Stars and
      Triple IR sequences.

      Data To be Collected:

      MRI data to be collected will include:

      Left ventricular and right ventricular ejection fractions Left ventricular wall motion Edema
      Resting myocardial perfusion Pericardial adipose tissue volume T2 star values of pericardial
      fat pre-Feraheme and post-Feraheme Late gadolinium enhancement (scar assessment and
      distribution) Valvular assessment Extracardiac assessment - pericardial effusion, pleural
      effusion, ascites Vital signs (height, weight, blood pressure, heart rate, BSA) Additional
      Data to be collected if available from the clinical record. Left Heart catheterization
      Presence or absence of coronary artery disease. The general anatomy, lesion location and
      severity, presence, location and type of stents, left ventricular end diastolic pressure,
      systemic blood pressure, aortic valve gradient Echocardiogram Ejection fraction Regional wall
      motion abnormalities Inducible ischemia if a stress echo was performed Nuclear Stress study
      Presence or absence of ischemia or infarction Distribution of perfusion abnormalities.
      Ejection fraction TID (transient ischemic dilatation) End Diastolic Volume End Systolic
      Volume Medical History (Presence or Absence of ) Sociodemographic information (age,
      race/ethnicity, etc) HIV related medical information Myocardial Infarction
      Hypercholesterolemia Hypertension Ventricular Tachycardia Stent Placement Bypass Surgery
      Diabetes Peripheral Vascular Disease Stroke Smoking (Lifetime Pack-year history and Current
      status) Family History of Heart Disease Medications Current use in the last 30 days of
      Anti-hypertensive (Beta Blockers, Calcium Channel Blockers, Ace Inhibitors, Angiotensin
      Receptor Blockers, Alpha Antagonists) Current use in the last 30 days of Diuretics Lifetime
      use of Statins Current use in the last 30 days of Insulin or other anti-diabetic medications
      Lifetime use of Antiretroviral Therapy Laboratory Results HIV-1 Viral Load in the last year
      Nadir CD4 Count and CD4 count in the last year (include percentages) CD8/CD8 percent in the
      last year Troponins ( around time of MI if applicable) Most recent Creatinine within 90 days
      of study entry Most recent BUN within 90 days of study entry If subject has diabetes,
      hemoglobin A1C or Fructosamine levels in the last year.

      Primary endpoints Pericardial adipose tissue volume Change in T2 star value (assessment for
      iron deposition as a marker for inflammation) Secondary endpoints Correlation of inflammatory
      biomarkers with Pericardial adipose tissue volume and change in T2 star value Correlation of
      prior HIV related and Coronary Heart Disease risk factors and events with inflammatory
      biomarkers, pericardial adipose tissue volume and change in T2 star value.

      Data Analysis Data will be stored in a RedCap data base. Statistical analysis will be
      performed using MedCalc. Continuous variables will be analyzed using analysis of Variance
      (ANOVA). Non-continuous variables will be analyzed using chi square tests.

      Data Monitoring This study will be monitored by a trained coordinator not involved in the
      research project after enrollment of the first subject, fifth subject and last subject. The
      monitoring plan will include 100% verification of consent process and inclusion and exclusion
      criteria. Monitoring for appropriate documentation and collection of study data will be done
      on the first three subjects and after completion of the last subjects on all study
      participants. Additional monitoring will be conducted based on risk based assessment of the
      monitor.

      Data Safety Monitoring Board (DSMB) No DSMB will be established for this study. The risks of
      MRI and phlebotomy are low and there are no test agents being used that are not Food and Drug
      Administration (FDA) approved. The investigators will monitor closely for adverse events and
      if an unanticipated number or severity of events occur, the Institutional Review Board (IRB)
      will be notified and a DSMB will be convened.

      Data Storage and Confidentiality:

      Participant medical information will be stored electronically in a Redcap database. Each
      subject will have a unique study ID assigned to their data.

      The names and medical record numbers of the research participants will be kept under lock and
      key and separate from the actual research data in recap. No identifying information will be
      present in the research database.

      Access to participant medical information contained within this research project will be
      restricted to involved investigators and study personnel.

      Password protection of data files will be used. Any paper based data pertaining to
      individuals will be stored in a locked secure location.

      De-identified participant medical record information will be stored for an indefinite period
      of time per institutional policies at the University of Cincinnati (UC).

      Setting: University of Cincinnati Medical Center, and affiliated MRI facilities

      Laboratory Methods and Facilities:

      Peripheral blood mononuclear cells, plasma and serum will be obtained and stored for
      subsequent measurement of; hsCRP, IL-6, D-dimer, sCD163, CXCL10, flow cytometry for measures
      of monocyte activation and additional studies.

      DNA will be isolated and may be sent for genetic testing related to inflammation, lipid
      disorders and atherosclerosis.

      Fasting lipids will be obtained on the day of the cardiac MRI CD4 counts and HIV RNA
      quantitation obtained within 60 days of the cardiac MRI will be recorded.

      Estimated Period of Time to Complete the Study: 12 months, ending June 30, 2015.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pericardial adipose tissue volume</measure>
    <time_frame>On baseline imaging</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adipose spin spin relaxivity as measured by T2 star time</measure>
    <time_frame>At baseline and 48-72 hours later</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>HIV+/CAD+</arm_group_label>
    <description>HIV+/CAD+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+/CAD-</arm_group_label>
    <description>HIV+/CAD-</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-/CAD+</arm_group_label>
    <description>HIV-/CAD+</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-/CAD-</arm_group_label>
    <description>HIV-/CAD-</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected persons with a history of a positive or negative coronary angiography or
        cardiac computed tomography angiography (CTA) will be invited to participate in this study
        from the Infectious Diseases Center practice where there are 1800 persons receiving care.
        Additionally 4 subjects will be recruited from the cardiology practice at UCMC who have
        coronary artery disease but do not have HIV.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  History of HIV disease or no history of HIV

          -  Prior history of left heart catheterization or CTA indicating the presence or absence
             of CAD.

        Exclusion Criteria:

          -  Unable to have a contrast enhanced cardiac MRI, (i.e. ferromagnetic foreign body,
             inability to follow verbal instructions, prior history of allergic reactions to
             gadolinium, history of nephrogenic systemic fibrosis, severe renal dysfunction GFR&lt;30
             ml/min/1.73 m2, or severe claustrophobia/anxiety);

          -  Chronic kidney disease patient undergoing hemodialysis or peritoneal dialysis

          -  Allergy to Iron Compounds;

          -  Pregnant females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Harris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David M Harris, MD</last_name>
    <phone>513 558-3476</phone>
    <email>harri2di@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Conway, CNP</last_name>
    <phone>513-558-3476</phone>
    <email>conwaygg@ucmail.uc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ginger Conway, MSN, RN, CNP</last_name>
      <phone>513-558-3476</phone>
      <email>conwaygg@ucmail.uc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009 Dec 1;54(23):2129-38. doi: 10.1016/j.jacc.2009.09.009. Review.</citation>
    <PMID>19942084</PMID>
  </reference>
  <reference>
    <citation>Martínez E, Tuset M, Milinkovic A, Miró JM, Gatell JM. Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy. Antivir Ther. 2004 Oct;9(5):649-63. Review.</citation>
    <PMID>15535403</PMID>
  </reference>
  <reference>
    <citation>Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol. 1993 May-Jun;144(3):225-31.</citation>
    <PMID>8356344</PMID>
  </reference>
  <reference>
    <citation>Tabib A, Greenland T, Mercier I, Loire R, Mornex JF. Coronary lesions in young HIV-positive subjects at necropsy. Lancet. 1992 Sep 19;340(8821):730.</citation>
    <PMID>1355828</PMID>
  </reference>
  <reference>
    <citation>Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12. Epub 2007 Apr 24.</citation>
    <PMID>17456578</PMID>
  </reference>
  <reference>
    <citation>Post WS, Budoff M, Kingsley L, Palella FJ Jr, Witt MD, Li X, George RT, Brown TT, Jacobson LP. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014 Apr 1;160(7):458-67. doi: 10.7326/M13-1754.</citation>
    <PMID>24687069</PMID>
  </reference>
  <reference>
    <citation>Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sørensen HT, Gerstoft J. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007 Jun 15;44(12):1625-31. Epub 2007 May 10.</citation>
    <PMID>17516408</PMID>
  </reference>
  <reference>
    <citation>Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):268-73. doi: 10.1097/QAI.0b013e3181a9992c.</citation>
    <PMID>19387353</PMID>
  </reference>
  <reference>
    <citation>Mangili A, Polak JF, Quach LA, Gerrior J, Wanke CA. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis. 2011 Feb;214(2):468-73. doi: 10.1016/j.atherosclerosis.2010.11.013. Epub 2010 Nov 17.</citation>
    <PMID>21130995</PMID>
  </reference>
  <reference>
    <citation>Coll B, Parra S, Alonso-Villaverde C, Aragonés G, Montero M, Camps J, Joven J, Masana L. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke. 2007 Sep;38(9):2477-84. Epub 2007 Aug 2.</citation>
    <PMID>17673719</PMID>
  </reference>
  <reference>
    <citation>Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN. Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS. 2008 Aug 20;22(13):1615-24. doi: 10.1097/QAD.0b013e328300581d.</citation>
    <PMID>18670221</PMID>
  </reference>
  <reference>
    <citation>Lang S, Mary-Krause M, Simon A, Partisani M, Gilquin J, Cotte L, Boccara F, Costagliola D; French Hospital Database on HIV (FHDH)–ANRS CO4. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012 Aug;55(4):600-7. Epub 2012 May 18.</citation>
    <PMID>22610928</PMID>
  </reference>
  <reference>
    <citation>Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation. 2010 Feb 9;121(5):651-8. doi: 10.1161/CIRCULATIONAHA.109.898585. Epub 2010 Jan 25.</citation>
    <PMID>20100969</PMID>
  </reference>
  <reference>
    <citation>Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003 May 23;17(8):1179-93.</citation>
    <PMID>12819520</PMID>
  </reference>
  <reference>
    <citation>Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. Review.</citation>
    <PMID>15843671</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.</citation>
    <PMID>18997196</PMID>
  </reference>
  <reference>
    <citation>Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, Gange SJ. C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med. 2006 Jan 9;166(1):64-70.</citation>
    <PMID>16401812</PMID>
  </reference>
  <reference>
    <citation>Feldman JG, Goldwasser P, Holman S, DeHovitz J, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):210-4.</citation>
    <PMID>12571532</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol &lt;70 mg/dl and C-reactive protein &lt;2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17;45(10):1644-8. Epub 2005 Apr 25.</citation>
    <PMID>15893181</PMID>
  </reference>
  <reference>
    <citation>Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ; West of Scotland Coronary Prevention Study Group. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1529-34. Epub 2004 Jun 17.</citation>
    <PMID>15205218</PMID>
  </reference>
  <reference>
    <citation>Lowe GD, Sweetnam PM, Yarnell JW, Rumley A, Rumley C, Bainton D, Ben-Shlomo Y. C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1957-62. Epub 2004 Aug 12.</citation>
    <PMID>15308549</PMID>
  </reference>
  <reference>
    <citation>Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008 Oct 21;5(10):e203. doi: 10.1371/journal.pmed.0050203.</citation>
    <PMID>18942885</PMID>
  </reference>
  <reference>
    <citation>Park IW, Wang JF, Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood. 2001 Jan 15;97(2):352-8.</citation>
    <PMID>11154208</PMID>
  </reference>
  <reference>
    <citation>Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006 Mar;185(1):1-11. Epub 2005 Nov 16. Review.</citation>
    <PMID>16297390</PMID>
  </reference>
  <reference>
    <citation>Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, Rosenberg ES, Williams KC, Grinspoon S. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011 Oct 15;204(8):1227-36. doi: 10.1093/infdis/jir520.</citation>
    <PMID>21917896</PMID>
  </reference>
  <reference>
    <citation>Sani MU. Myocardial disease in human immunodeficiency virus (HIV) infection: a review. Wien Klin Wochenschr. 2008;120(3-4):77-87. doi: 10.1007/s00508-008-0935-3. Review.</citation>
    <PMID>18322768</PMID>
  </reference>
  <reference>
    <citation>Raj V, Joshi S, Pennell DJ. Images in Cardiovascular Medicine. Cardiac magnetic resonance of acute myocarditis in an human immunodeficiency virus patient presenting with acute chest pain syndrome. Circulation. 2010 Jun 29;121(25):2777-9. doi: 10.1161/CIRCULATIONAHA.109.888099.</citation>
    <PMID>20585023</PMID>
  </reference>
  <reference>
    <citation>Restrepo CS, Diethelm L, Lemos JA, Velásquez E, Ovella TA, Martinez S, Carrillo J, Lemos DF. Cardiovascular complications of human immunodeficiency virus infection. Radiographics. 2006 Jan-Feb;26(1):213-31. Review.</citation>
    <PMID>16418253</PMID>
  </reference>
  <reference>
    <citation>Konishi M, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Matsubara J, Matsuzawa Y, Sumida H, Nagayoshi Y, Nakaura T, Awai K, Yamashita Y, Jinnouchi H, Matsui K, Kimura K, Umemura S, Ogawa H. Association of pericardial fat accumulation rather than abdominal obesity with coronary atherosclerotic plaque formation in patients with suspected coronary artery disease. Atherosclerosis. 2010 Apr;209(2):573-8. doi: 10.1016/j.atherosclerosis.2009.10.008. Epub 2009 Oct 12.</citation>
    <PMID>19892354</PMID>
  </reference>
  <reference>
    <citation>de Vos AM, Prokop M, Roos CJ, Meijs MF, van der Schouw YT, Rutten A, Gorter PM, Cramer MJ, Doevendans PA, Rensing BJ, Bartelink ML, Velthuis BK, Mosterd A, Bots ML. Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women. Eur Heart J. 2008 Mar;29(6):777-83. Epub 2007 Dec 20.</citation>
    <PMID>18156138</PMID>
  </reference>
  <reference>
    <citation>Katsiki N, Mikhailidis DP, Wierzbicki AS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol. 2013 Jul;28(4):458-63. doi: 10.1097/HCO.0b013e3283605fba. Review.</citation>
    <PMID>23591557</PMID>
  </reference>
  <reference>
    <citation>Gronemeyer SA, Steen RG, Kauffman WM, Reddick WE, Glass JO. Fast adipose tissue (FAT) assessment by MRI. Magn Reson Imaging. 2000 Sep;18(7):815-8.</citation>
    <PMID>11027874</PMID>
  </reference>
  <reference>
    <citation>Machann J, Thamer C, Schnoedt B, Haap M, Haring HU, Claussen CD, Stumvoll M, Fritsche A, Schick F. Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging. 2005 Apr;21(4):455-62.</citation>
    <PMID>15778954</PMID>
  </reference>
  <reference>
    <citation>Nelson AJ, Worthley MI, Psaltis PJ, Carbone A, Dundon BK, Duncan RF, Piantadosi C, Lau DH, Sanders P, Wittert GA, Worthley SG. Validation of cardiovascular magnetic resonance assessment of pericardial adipose tissue volume. J Cardiovasc Magn Reson. 2009 May 5;11:15. doi: 10.1186/1532-429X-11-15.</citation>
    <PMID>19416534</PMID>
  </reference>
  <reference>
    <citation>Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, Aletras A, Laissy JP, Paterson I, Filipchuk NG, Kumar A, Pauschinger M, Liu P; International Consensus Group on Cardiovascular Magnetic Resonance in Myocarditis. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol. 2009 Apr 28;53(17):1475-87. doi: 10.1016/j.jacc.2009.02.007.</citation>
    <PMID>19389557</PMID>
  </reference>
  <reference>
    <citation>Rajiah P. Cardiac MRI: Part 2, pericardial diseases. AJR Am J Roentgenol. 2011 Oct;197(4):W621-34. doi: 10.2214/AJR.10.7265. Review.</citation>
    <PMID>21940533</PMID>
  </reference>
  <reference>
    <citation>Weinsaft JW, Kim HW, Shah DJ, Klem I, Crowley AL, Brosnan R, James OG, Patel MR, Heitner J, Parker M, Velazquez EJ, Steenbergen C, Judd RM, Kim RJ. Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol. 2008 Jul 8;52(2):148-57. doi: 10.1016/j.jacc.2008.03.041.</citation>
    <PMID>18598895</PMID>
  </reference>
  <reference>
    <citation>Schelbert EB, Cao JJ, Sigurdsson S, Aspelund T, Kellman P, Aletras AH, Dyke CK, Thorgeirsson G, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Arai AE. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012 Sep 5;308(9):890-6. doi: 10.1001/2012.jama.11089.</citation>
    <PMID>22948699</PMID>
  </reference>
  <reference>
    <citation>Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, Ball SG, Plein S. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012 Feb 4;379(9814):453-60. doi: 10.1016/S0140-6736(11)61335-4. Epub 2011 Dec 22.</citation>
    <PMID>22196944</PMID>
  </reference>
  <reference>
    <citation>Kellman P, Aletras AH, Mancini C, McVeigh ER, Arai AE. T2-prepared SSFP improves diagnostic confidence in edema imaging in acute myocardial infarction compared to turbo spin echo. Magn Reson Med. 2007 May;57(5):891-7.</citation>
    <PMID>17457880</PMID>
  </reference>
  <reference>
    <citation>Kellman P, Arai AE. Imaging sequences for first pass perfusion --a review. J Cardiovasc Magn Reson. 2007;9(3):525-37. Review.</citation>
    <PMID>17365232</PMID>
  </reference>
  <reference>
    <citation>Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, Aletras AH, Arai AE. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Circ Cardiovasc Imaging. 2010 Nov;3(6):743-52. doi: 10.1161/CIRCIMAGING.108.835793. Epub 2010 Sep 16.</citation>
    <PMID>20847191</PMID>
  </reference>
  <reference>
    <citation>Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008 Nov 4;52(19):1574-80. doi: 10.1016/j.jacc.2008.06.049.</citation>
    <PMID>19007595</PMID>
  </reference>
  <reference>
    <citation>Arai AE. The cardiac magnetic resonance (CMR) approach to assessing myocardial viability. J Nucl Cardiol. 2011 Dec;18(6):1095-102. doi: 10.1007/s12350-011-9441-5. Review.</citation>
    <PMID>21882082</PMID>
  </reference>
  <reference>
    <citation>Sandstede J, Lipke C, Beer M, Hofmann S, Pabst T, Kenn W, Neubauer S, Hahn D. Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol. 2000;10(3):438-42.</citation>
    <PMID>10756992</PMID>
  </reference>
  <reference>
    <citation>Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008 Mar 18;117(11):1436-48. doi: 10.1161/CIRCULATIONAHA.107.653576. Review.</citation>
    <PMID>18347220</PMID>
  </reference>
  <reference>
    <citation>Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004 Feb;147(2):218-23.</citation>
    <PMID>14760316</PMID>
  </reference>
  <reference>
    <citation>Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989 Jan;152(1):167-73.</citation>
    <PMID>2783272</PMID>
  </reference>
  <reference>
    <citation>Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11(11):2319-31. Review.</citation>
    <PMID>11702180</PMID>
  </reference>
  <reference>
    <citation>Chapon C, Franconi F, Lemaire L, Marescaux L, Legras P, Saint-André JP, Denizot B, Le Jeune JJ. High field magnetic resonance imaging evaluation of superparamagnetic iron oxide nanoparticles in a permanent rat myocardial infarction. Invest Radiol. 2003 Mar;38(3):141-6.</citation>
    <PMID>12595793</PMID>
  </reference>
  <reference>
    <citation>Sosnovik DE, Nahrendorf M, Deliolanis N, Novikov M, Aikawa E, Josephson L, Rosenzweig A, Weissleder R, Ntziachristos V. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation. 2007 Mar 20;115(11):1384-91. Epub 2007 Mar 5.</citation>
    <PMID>17339546</PMID>
  </reference>
  <reference>
    <citation>Ho C, Hitchens TK. A non-invasive approach to detecting organ rejection by MRI: monitoring the accumulation of immune cells at the transplanted organ. Curr Pharm Biotechnol. 2004 Dec;5(6):551-66. Review.</citation>
    <PMID>15579044</PMID>
  </reference>
  <reference>
    <citation>Oweida AJ, Dunn EA, Foster PJ. Cellular imaging at 1.5 T: detecting cells in neuroinflammation using active labeling with superparamagnetic iron oxide. Mol Imaging. 2004 Apr;3(2):85-95.</citation>
    <PMID>15296673</PMID>
  </reference>
  <reference>
    <citation>Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med. 2003 Aug;50(2):309-14.</citation>
    <PMID>12876707</PMID>
  </reference>
  <reference>
    <citation>Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK; European Society of cardiology; Soceity for Cardiovascular Magnetic Resonance. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J Cardiovasc Magn Reson. 2004;6(4):727-65.</citation>
    <PMID>15646878</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>David Harris</investigator_full_name>
    <investigator_title>Cardiac Imaging Director</investigator_title>
  </responsible_party>
  <keyword>Cardiac Magnetic Resonance (CMR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only researchers approved on the IRB protocol will have access to the data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

